Hybrid Pharm is the first brick-and-mortar storefront in Ontario to carry British Columbia’s #1 selling CBD vape and all Glacial Gold(TM) products
Vancouver, British Columbia–(Newsfile Corp. – March 31, 2022) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf“, “OILS“, or the “Company“), a federally regulated manufacturer and distributor of cannabis vapes and oils, today announced it is supplying Hybrid Pharm Inc. (“Hybrid Pharm“), Canada’s first brick-and-mortar pharmacy distributing medical cannabis products, with the entire suite of cannabinoid-based products under the Company’s award-winning prohibition-era brand Glacial Gold™.
To view an enhanced version of this graphic, please visit:
“Hybrid Pharm’s dedication to the plant, patient education, and unique model of distribution through brick-and-mortar pharmacy made it a must for our Company when considering making Glacial Gold available for medical use,” said Nextleaf CEO Paul Pedersen. “We are proud to have Glacial Gold products distributed by Hybrid Pharm in store and online, and excited to support increased access to medical cannabis through the growth of Hybrid’s pharmacy distribution model across Canada.”
Ottawa-based Hybrid Pharm deploys a unique model among pharmacies in Canada, by providing medical cannabis patients with a full in-store experience while still offering a Tele-Medicine platform. Certified medical staff ensure patients’ cannabis treatments are optimized through close monitoring, drug interaction checks, and quality control processes.
Hybrid Pharm’s pharmacists are equipped to help patients learn about cannabis and their needs, including dosage forms and side effects. Patients with Hybrid Pharm have access to informative workshops and seminars through their website. “Patients deserve an outlet to discuss their medical cannabis needs and like all drugs, medical cannabis is best dispensed by qualified pharmacists. Recreational cannabis stores cannot offer this expertise,” said Dr. Rahim Dhalla, Chief Executive Officer of Hybrid Pharm.
Medical cannabis has become an important component of Canadian healthcare, with $116 million of medical cannabis purchases reimbursed by the Federal Government through Veterans Affairs Canada in 2021.
About Hybrid Pharm
Hybrid Pharm is a modern wellness pharmacy located in the Westboro neighbourhood of Ottawa. We specialize in providing a multi-modal approach to healthcare including access to medical cannabis, pharmacy and compounding as well as our wellness and lifestyle modification programming. Our certified staff is happy to help guide your way to a healthy future. Please visit www.hybridpharm.com for more information.
Nextleaf is a federally regulated manufacturer and distributor of cannabis vapes and oils under its award-winning prohibition-era brand, Glacial Gold™. The Company’s multi-patented ingredient processing technology transforms cannabis and hemp biomass into high-purity distillate at an industrial scale. Nextleaf is a low-cost producer of cannabis oils, and supplier of THC and CBD ingredients to qualified wholesale partners across Canada. Nextleaf is the first publicly traded company to be issued a U.S. patent for the industrial extraction and purification of cannabinoids. The Company has been issued 17 U.S. patents, and over 90 patents globally, on cannabinoid processing including distillation and acetylation. Nextleaf develops proprietary cannabinoid-based formulations and delivery technology through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. For more information visit www.nextleafsolutions.com and www.Glacial.Gold
For more information please contact:
Jason McBride, Corporate Development
604-283-2301 (ext. 219)
On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO
Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, receipt of the Dealer’s Licence within the anticipated timeframe or at all, the activities the Company expects to conduct if the Dealer’s Licence, the ability of the Company to develop and protect intellectual property relating to psychedelics, the expected benefits to the Company if the Dealer’s Licence is received, the Dealer’s License assisting the company in obtaining a unique position for the Company to develop a suite of standardized plant-derived drugs, the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.
 https://www.veterans.gc.ca/eng/about-vac/research/research-directorate/publications/reports/cmp – 2021 data pertains to the CMP reimbursement program by fiscal year. The last quarter for fiscal year 2021/22 (from January 1, 2022 to March 31, 2022) is not yet complete and therefore not reflected in the numbers.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/118730